Literature DB >> 29933222

High-throughput lipidomics characterize key lipid molecules as potential therapeutic targets of Kaixinsan protects against Alzheimer's disease in APP/PS1 transgenic mice.

Hong-Lei Gao1, Ai-Hua Zhang1, Jing-Bo Yu1, Hui Sun1, Ling Kong1, Xiang-Qian Wang1, Guang-Li Yan1, Liang Liu2, Xi-Jun Wang3.   

Abstract

Alzheimer's disease (AD) is still a major problem nowadays. Under the circumstance of many chemical drugs have poor effects on AD, traditional Chinese medicine has become a hot spot for us due to its multi-target and multi-path advantages. To explore the potential therapeutic targets of Kaixinsan (KXS) protects against AD in APP/PS1 transgenic mice model. All mice were divided into three groups: control group, model group and KXS group. Orally given KXS from two month old, and the control and model groups were given the same dose of distilled water. We collected all mice's serum samples at the 12th month age to determine the lipid markers of AD by compare with the model and control groups in full-scan analysis based on high-throughput serum lipidomics technology. Then we found the lipid molecules called back by KXS from the KXS protects against AD. Compared with the control group, the metabolic profile of the model mice was obviously disordered, and we identified 16 lipid-related biomarkers associated with AD. After KXS treatment, the metabolic profiles of these disorders tended to recover compared with the model group. And we identified eight key lipid molecules, of which four had statistical significance. We found that the main perturbation pathways related to AD were linoleic acid metabolism, arachidonic acid metabolism and sphingolipid metabolism. All these metabolic pathways showed different degrees of rotation after KXS administration. Through the pathways analysis, we found 4 lipids molecules with significant differences, which could be used as new targets for the treatment of AD.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APP/PS1 transgenic mice; Alzheimer's disease (AD); Kaixinsan (KXS); Lipidomics; Traditional Chinese medicine

Mesh:

Substances:

Year:  2018        PMID: 29933222     DOI: 10.1016/j.jchromb.2018.06.032

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  19 in total

1.  Interplay between Alzheimer's disease and global glucose metabolism revealed by the metabolic profile alterations of pancreatic tissue and serum in APP/PS1 transgenic mice.

Authors:  Xia Liu; Wei Wang; Hua-Li Chen; Hai-Yan Zhang; Nai-Xia Zhang
Journal:  Acta Pharmacol Sin       Date:  2019-05-14       Impact factor: 6.150

2.  High-throughput liquid chromatography mass-spectrometry-driven lipidomics discover metabolic biomarkers and pathways as promising targets to reveal the therapeutic effects of the Shenqi pill.

Authors:  Wen-Xiu Li; Ai-Hua Zhang; Xiao-Hang Zhou; Yang Nan; Qi Liu; Hui Sun; Heng Fang; Xi-Jun Wang
Journal:  RSC Adv       Date:  2020-01-13       Impact factor: 4.036

3.  Kai-Xin-San Inhibits Tau Pathology and Neuronal Apoptosis in Aged SAMP8 Mice.

Authors:  Ya-Nan Jiao; Jing-Sheng Zhang; Wen-Jun Qiao; Shu-Yu Tian; Yi-Bin Wang; Chun-Yan Wang; Yan-Hui Zhang; Qi Zhang; Wen Li; Dong-Yu Min; Zhan-You Wang
Journal:  Mol Neurobiol       Date:  2022-03-18       Impact factor: 5.682

4.  High-throughput lipidomics reveal mirabilite regulating lipid metabolism as anticancer therapeutics.

Authors:  Hong-Lian Zhang; Ai-Hua Zhang; Xiao-Hang Zhou; Hui Sun; Xiang-Qian Wang; Liu Liang; Xi-Jun Wang
Journal:  RSC Adv       Date:  2018-10-18       Impact factor: 4.036

5.  The Impact of the hAPP695SW Transgene and Associated Amyloid-β Accumulation on Murine Hippocampal Biochemical Pathways.

Authors:  Mona Khorani; Gerd Bobe; Donald G Matthews; Armando Alcazar Magana; Maya Caruso; Nora E Gray; Joseph F Quinn; Jan F Stevens; Amala Soumyanath; Claudia S Maier
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

6.  Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats.

Authors:  Yuanjun Deng; Maoxing Pan; Huan Nie; Chuiyang Zheng; Kairui Tang; Yupei Zhang; Qinhe Yang
Journal:  Molecules       Date:  2019-10-31       Impact factor: 4.411

7.  Network Pharmacology Study of Heat-Clearing and Detoxifying Traditional Chinese Medicine for Alzheimer's Disease.

Authors:  Hongxing Li; Xinyue Zhang; Lili Gu; Ningzi Wu; Lingxi Zhang; Jiaqi Lu; Qin Li
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-24       Impact factor: 2.629

8.  Systems Pharmacology Approach to Investigate the Mechanism of Kai-Xin-San in Alzheimer's Disease.

Authors:  Yunxia Luo; Dongli Li; Yanfang Liao; Chuipu Cai; Qihui Wu; Hanzhong Ke; Xinning Liu; Huilin Li; Honghai Hong; Yumin Xu; Qi Wang; Jiansong Fang; Shuhuan Fang
Journal:  Front Pharmacol       Date:  2020-04-03       Impact factor: 5.810

9.  Identification of key lipid metabolites during metabolic dysregulation in the diabetic retinopathy disease mouse model and efficacy of Keluoxin capsule using an UHPLC-MS-based non-targeted lipidomics approach.

Authors:  Nan Ge; Ling Kong; Ai-Hua Zhang; Ye Sun; Man-Qian Zhao; Bo Zhang; Lei Xu; Xiao Ke; Hui Sun; Xi-Jun Wang
Journal:  RSC Adv       Date:  2021-02-01       Impact factor: 3.361

Review 10.  Chinmedomics, a new strategy for evaluating the therapeutic efficacy of herbal medicines.

Authors:  Ying Han; Hui Sun; Aihua Zhang; Guangli Yan; Xi-Jun Wang
Journal:  Pharmacol Ther       Date:  2020-09-18       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.